These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 10589783

  • 1. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
    Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC.
    Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
    [Abstract] [Full Text] [Related]

  • 2. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG, Schelling ME, Hosick HL.
    Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
    [Abstract] [Full Text] [Related]

  • 3. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

  • 4. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
    Jhabvala-Romero F, Evans A, Guo S, Denton M, Clinton GM.
    Oncogene; 2003 Nov 06; 22(50):8178-86. PubMed ID: 14603258
    [Abstract] [Full Text] [Related]

  • 5. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
    Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX.
    Cancer Res; 1996 Mar 15; 56(6):1457-65. PubMed ID: 8640840
    [Abstract] [Full Text] [Related]

  • 6. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG, Ethier SP.
    Cell Growth Differ; 1996 May 15; 7(5):551-61. PubMed ID: 8732665
    [Abstract] [Full Text] [Related]

  • 7. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
    Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ.
    Oncogene; 1999 Oct 28; 18(44):6050-62. PubMed ID: 10557094
    [Abstract] [Full Text] [Related]

  • 8. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer.
    Campiglio M, Ali S, Knyazev PG, Ullrich A.
    J Cell Biochem; 1999 Jun 15; 73(4):522-32. PubMed ID: 10733345
    [Abstract] [Full Text] [Related]

  • 9. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
    Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA.
    Oncogene; 2000 Jul 20; 19(31):3460-9. PubMed ID: 10918604
    [Abstract] [Full Text] [Related]

  • 10. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 20; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 11. Src family kinases and HER2 interactions in human breast cancer cell growth and survival.
    Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ.
    Oncogene; 2001 Mar 22; 20(12):1465-75. PubMed ID: 11313890
    [Abstract] [Full Text] [Related]

  • 12. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
    Ethier SP, Kokeny KE, Ridings JW, Dilts CA.
    Cancer Res; 1996 Feb 15; 56(4):899-907. PubMed ID: 8631031
    [Abstract] [Full Text] [Related]

  • 13. Association between growth factor heregulin1α and receptors in growth of ovarian cancer cell line with high potentiality of peritoneal dissemination.
    Nishiyama H, Soeda S, Watanabe T, Fujimori K.
    Fukushima J Med Sci; 2012 Feb 15; 58(1):22-32. PubMed ID: 22790889
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas.
    Balañá ME, Lupu R, Labriola L, Charreau EH, Elizalde PV.
    Oncogene; 1999 Nov 04; 18(46):6370-9. PubMed ID: 10597237
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40.
    Furger C, Fiddes RJ, Quinn DI, Bova RJ, Daly RJ, Sutherland RL.
    Cancer Res; 1998 May 01; 58(9):1773-8. PubMed ID: 9581810
    [Abstract] [Full Text] [Related]

  • 19. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
    Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA, Bast RC.
    Oncogene; 2001 Dec 13; 20(57):8258-69. PubMed ID: 11781840
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.